Remsima SC
Scope
Date
~
-
Bio & PharmaCelltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Apr 19, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Feb 07, 2024 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion to supply Remsima to Brazil gov’t in three-year row
South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the B...
Nov 10, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion gets FDA approval for Remsima SC
South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...
Oct 23, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare wins Remsima order in France, Italy
South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...
Oct 18, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion signs largest-ever quarterly deal with global sales affiliate
Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...
Sep 25, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion’s Remsima SC praised in Europe as preferred biosimilar
MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...
Jun 02, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare launches Remsima SC in Brazil
South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...
May 22, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & PharmaCelltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & PharmaCelltrion to seek FDA approval for sale of Remsima SC by year-end
Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients...
Nov 28, 2022 (Gmt+09:00)
-
EarningsCelltrion's Q3 earnings boosted by Remsima sales in Europe
South Korean biopharmaceutical giant Celltrion Inc. announced 654.6 billion won ($478.2 million) in revenue and 213.8 billion won in operating profi...
Nov 09, 2022 (Gmt+09:00)
-
Bio & PharmaCelltrion Healthcare logs record-high Q2 revenue on back of Remsima
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.’s global marketing affiliate, posted its record-high second-quar...
Aug 17, 2022 (Gmt+09:00)
